Fig 5. Nucleocapsid- and Spike-specific IgG levels in saliva of newly positive, asymptomatic individuals versus prior positive, asymptomatic individuals.

Saliva from New^POS individuals infected with either CoV2^US (n = 16) or CoV2^Alpha (n = 15), as well as PCR^NEG saliva from individuals who had been infected 2–37 weeks prior (Prior^POS, n = 402) with either CoV2^US, CoV2^Alpha, or a non-VOC, were used to measure the concentrations of (A) Nucleocapsid-specific IgG, (B) Spike- specific IgG, and (C) Spike RBD-specific IgG. Data from Prior^POS individuals are subdivided based on whether the individual remained unvaccinated up until the day of saliva collection (Vax^NEG, n = 257) or was vaccinated prior to the day of saliva collection (Vax^POS, n = 145). * p≤ 0.05, as determined by unpaired Wilcoxon test with Benjamini-Hochberg adjustment. (D-E) For those individuals who were Prior^POSVax^NEG, the relationship between time since original positivity (i.e. the number of days since the individual was first deemed PCR^POS by our program) and their current (D) saliva IgG^N level and (E) saliva IgG^Spike level at the time of sampling. Graph insets indicates the Multiple R-squared value associated with the linear regression model of the respective data set (i.e. the % variation in either saliva IgG^N or IgG^Spike that can be explained by the indicated time since positivity), as well as its p-value (i.e. the significance of the linear model as a whole).